StreetInsider.com News Articles

Knight Therapeutics Reports Second Quarter 2026 Results

Thu, 06 Aug 2026 06:30:00 -0400

Increased 2026 guidance and expect revenues of $540 million to $560 million
Achieved six month record-high revenues of $293 million and Adjusted EBITDA1 of $52 million

MONTREAL, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a pan-American (ex-US) pharmaceutical company, today reported financial results for its second quarter ended June 30, 2026. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified.

Q2-26 Highlights

Financial Results - IFRS

Revenues were $144,212, an

Knight Therapeutics Reports Second Quarter 2026 Results

Thu, 06 Aug 2026 06:30:00 -0400

Increased 2026 guidance and expect revenues of $540 million to $560 million
Achieved six month record-high revenues of $293 million and Adjusted EBITDA1 of $52 million

Q2-26 Highlights

Financial Results - IFRS

Revenues were $144,212, an

Knight Therapeutics Reports Second Quarter 2026 Results

Thu, 06 Aug 2026 06:30:00 -0400

Increased 2026 guidance and expect revenues of $540 million to $560 million
Achieved six month record-high revenues of $293 million and Adjusted EBITDA1 of $52 million

Q2-26 Highlights

Financial Results - IFRS

Revenues were $144,212, an

Knight Therapeutics Reports Second Quarter 2026 Results

Thu, 06 Aug 2026 06:30:00 -0400

Increased 2026 guidance and expect revenues of $540 million to $560 million
Achieved six month record-high revenues of $293 million and Adjusted EBITDA1 of $52 million

Q2-26 Highlights

Financial Results - IFRS

Revenues were $144,212, an

Knight Therapeutics Reports Second Quarter 2026 Results

Thu, 06 Aug 2026 06:30:00 -0400

Increased 2026 guidance and expect revenues of $540 million to $560 million
Achieved six month record-high revenues of $293 million and Adjusted EBITDA1 of $52 million

Q2-26 Highlights

Financial Results - IFRS

Revenues were $144,212, an

Knight Therapeutics Reports Second Quarter 2026 Results

Thu, 06 Aug 2026 06:30:00 -0400

Increased 2026 guidance and expect revenues of $540 million to $560 million
Achieved six month record-high revenues of $293 million and Adjusted EBITDA1 of $52 million

Q2-26 Highlights

Financial Results - IFRS

Revenues were $144,212, an

Knight Therapeutics Reports Second Quarter 2026 Results

Thu, 06 Aug 2026 06:30:00 -0400

Increased 2026 guidance and expect revenues of $540 million to $560 million
Achieved six month record-high revenues of $293 million and Adjusted EBITDA1 of $52 million

Q2-26 Highlights

Financial Results - IFRS

Revenues were $144,212, an

Knight Therapeutics Reports Second Quarter 2026 Results

Thu, 06 Aug 2026 06:30:00 -0400

Increased 2026 guidance and expect revenues of $540 million to $560 million
Achieved six month record-high revenues of $293 million and Adjusted EBITDA1 of $52 million

Q2-26 Highlights

Financial Results - IFRS

Revenues were $144,212, an

Knight Therapeutics Reports Second Quarter 2026 Results

Thu, 06 Aug 2026 06:30:00 -0400

Increased 2026 guidance and expect revenues of $540 million to $560 million
Achieved six month record-high revenues of $293 million and Adjusted EBITDA1 of $52 million

Q2-26 Highlights

Financial Results - IFRS

Revenues were $144,212, an

Knight Therapeutics Reports Second Quarter 2026 Results

Thu, 06 Aug 2026 06:30:00 -0400

Increased 2026 guidance and expect revenues of $540 million to $560 million
Achieved six month record-high revenues of $293 million and Adjusted EBITDA1 of $52 million

Q2-26 Highlights

Financial Results - IFRS

Revenues were $144,212, an

Knight Therapeutics Reports Second Quarter 2026 Results

Thu, 06 Aug 2026 06:30:00 -0400

Increased 2026 guidance and expect revenues of $540 million to $560 million
Achieved six month record-high revenues of $293 million and Adjusted EBITDA1 of $52 million

Q2-26 Highlights

Financial Results - IFRS

Revenues were $144,212, an

Knight Therapeutics Reports Second Quarter 2026 Results

Thu, 06 Aug 2026 06:30:00 -0400

Increased 2026 guidance and expect revenues of $540 million to $560 million
Achieved six month record-high revenues of $293 million and Adjusted EBITDA1 of $52 million

Q2-26 Highlights

Financial Results - IFRS

Revenues were $144,212, an

Knight Therapeutics Reports Second Quarter 2026 Results

Thu, 06 Aug 2026 06:30:00 -0400

Increased 2026 guidance and expect revenues of $540 million to $560 million
Achieved six month record-high revenues of $293 million and Adjusted EBITDA1 of $52 million

Q2-26 Highlights

Financial Results - IFRS

Revenues were $144,212, an

Knight Therapeutics Reports Second Quarter 2026 Results

Thu, 06 Aug 2026 06:30:00 -0400

Increased 2026 guidance and expect revenues of $540 million to $560 million
Achieved six month record-high revenues of $293 million and Adjusted EBITDA1 of $52 million

Q2-26 Highlights

Financial Results - IFRS

Revenues were $144,212, an

Knight Therapeutics Reports Second Quarter 2026 Results

Thu, 06 Aug 2026 06:30:00 -0400

Increased 2026 guidance and expect revenues of $540 million to $560 million
Achieved six month record-high revenues of $293 million and Adjusted EBITDA1 of $52 million

Q2-26 Highlights

Financial Results - IFRS

Revenues were $144,212, an

Knight Therapeutics Reports Second Quarter 2026 Results

Thu, 06 Aug 2026 06:30:00 -0400

Increased 2026 guidance and expect revenues of $540 million to $560 million
Achieved six month record-high revenues of $293 million and Adjusted EBITDA1 of $52 million

Q2-26 Highlights

Financial Results - IFRS

Revenues were $144,212, an

Knight Therapeutics Reports Second Quarter 2026 Results

Thu, 06 Aug 2026 06:30:00 -0400

Increased 2026 guidance and expect revenues of $540 million to $560 million
Achieved six month record-high revenues of $293 million and Adjusted EBITDA1 of $52 million

Q2-26 Highlights

Financial Results - IFRS

Revenues were $144,212, an

Knight Therapeutics Reports Second Quarter 2026 Results

Thu, 06 Aug 2026 06:30:00 -0400

Increased 2026 guidance and expect revenues of $540 million to $560 million
Achieved six month record-high revenues of $293 million and Adjusted EBITDA1 of $52 million

Q2-26 Highlights

Financial Results - IFRS

Revenues were $144,212, an

Knight Therapeutics Reports Second Quarter 2026 Results

Thu, 06 Aug 2026 06:30:00 -0400

Increased 2026 guidance and expect revenues of $540 million to $560 million
Achieved six month record-high revenues of $293 million and Adjusted EBITDA1 of $52 million

Q2-26 Highlights

Financial Results - IFRS

Revenues were $144,212, an

Knight Therapeutics Reports Second Quarter 2026 Results

Thu, 06 Aug 2026 06:30:00 -0400

Increased 2026 guidance and expect revenues of $540 million to $560 million
Achieved six month record-high revenues of $293 million and Adjusted EBITDA1 of $52 million

Q2-26 Highlights

Financial Results - IFRS

Revenues were $144,212, an

Notice of Knight Therapeutics' Second Quarter 2026 Results Conference Call

Thu, 30 Jul 2026 06:30:00 -0400

MONTREAL, July 30, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-US) pharmaceutical company, will release its second quarter 2026 financial results on Thursday, August 6, 2026 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.

Date: Thursday, August 6, 2026

Time: 8:30 a.m. ET

Telephone: Toll Free: 1-888-699-1199 or International 1-416-945-7677

Webcast: www.knighttx.com or Webcast
This is a listen-only

Notice of Knight Therapeutics' Second Quarter 2026 Results Conference Call

Thu, 30 Jul 2026 06:30:00 -0400

Date: Thursday, August 6, 2026

Time: 8:30 a.m. ET

Telephone: Toll Free: 1-888-699-1199 or International 1-416-945-7677

Webcast: www.knighttx.com or Webcast
This is a listen-only

Notice of Knight Therapeutics' Second Quarter 2026 Results Conference Call

Thu, 30 Jul 2026 06:30:00 -0400

Date: Thursday, August 6, 2026

Time: 8:30 a.m. ET

Telephone: Toll Free: 1-888-699-1199 or International 1-416-945-7677

Webcast: www.knighttx.com or Webcast
This is a listen-only

Notice of Knight Therapeutics' Second Quarter 2026 Results Conference Call

Thu, 30 Jul 2026 06:30:00 -0400

Date: Thursday, August 6, 2026

Time: 8:30 a.m. ET

Telephone: Toll Free: 1-888-699-1199 or International 1-416-945-7677

Webcast: www.knighttx.com or Webcast
This is a listen-only

Knight Therapeutics repays $60M credit facility used for Paladin deal

Wed, 17 Jun 2026 17:30:08 -0400

Knight Therapeutics Inc. (TSX: GUD) announced it has repaid all amounts outstanding under its revolving credit facility with National Bank of Canada and a syndicate of lenders, according to a press release.

The company drew $60 million from the facility in June 2025 to fund the acquisition of Paladin. The repayment was completed within one year of that withdrawal.

The revolving credit facility carries a borrowing capacity of up to US$100 million, with an additional US$100 million accordion feature subject to certain conditions, bringing total potential capacity to US$200 million.

Chief Financial Officer Arvind Utchanah said the repayment "was funded by the strong